All News
ACR21 Best Abstracts We Saw - Day 3 (Monday)
The third day of ACR 2021 took a big leap in online content. Here is a compilation (with links) of presentations were the “ACRBest” as seen by our RheumNow faculty.
Read Article
#ACR21 L16 - Breakthrough #COVID19 in rheum pts
⭐️Breakthrough ifn ~4%, compared to 3% wo rheum disease. Statistically signif ⬆️ risk in RA, gout, polymyositis, vasculitis, multiple rheum disease
⭐️bDMARD, multiple AIRD risks
@Rheumnow https://t.co/cuM9LcEr4u https://t.co/Los2n7BoIn
Links:
Eric Dein ericdeinmd ( View Tweet)
Great case where the #COVIDvaccine was blamed, but he had a diet of doughnuts, steak&cheese sandwiches w/snack cakes, and popsicles. #ThievesMarket #ACR21 @rheumnow https://t.co/J78Nw5NhKs
TheDaoIndex KDAO2011 ( View Tweet)
Abst1625 #ACR21 @RheumNow study of kids w/covid induced MIS-C: 91% w/shock & GI ax, conjunctivitis & mucocutaneous involvement. ⬆️CRP,D-Dimer, Troponin, &BNP. On ECHO, 36% had myocardial dysfunction &27% coronary artery abnormalities. 64% required ICU admiss. Rx IVIG& steroids
Olga Petryna DrPetryna ( View Tweet)
#SARSCoV2 infections in vaccinated pts w/ #rheumaticdisease @rheum_covid @rheum_cat
👉🏼Most pts with breakthrough infections were on anti-metabolites or B-cell depleting therapies
👉🏼Encourage patients to get their #BoosterShot!
Abs#L04 #ACR21 @RheumNow
https://t.co/TAB4zrjPN1 https://t.co/z0gpsxN3xc
Mrinalini Dey DrMiniDey ( View Tweet)
#ACR21 Ab#L02 - #COVID19 vax in rheumatic pts:
❌No ⬆️ in disease activity scores post-vaccination
❌No serious adverse event
▶️Vax response 88% in RA, 78% in SLE, 87% other rheum diseases after 2 shots vs 100% controls
⭐️RTX and MMF ⬇️ responses
@Rheumnow https://t.co/BChhmW0jpy https://t.co/2q8IKRoYqW
Links:
Eric Dein ericdeinmd ( View Tweet)
#ACR21 Ab#L03: B cell depletors and #COVID19 vax:
⭐️B cell count <40 around vax had lower response to vax, than 40+ B-cell, independent of RTX or BEL
▶️ Timing of vax around B cell return can improve response
@Rheumnow https://t.co/1B7Bnb1QQu https://t.co/bKnfw6gD8O
Links:
Eric Dein ericdeinmd ( View Tweet)
Breakthrough COVID-19 in rheum pts: great data @rheum_covid
B-cell depleting agents overrepresented, esp in hospitalization in fully vaccinated - but plenty of others
Booster (& booster booster) vaccine doses + other mitigation badly needed!
@rheum_cat #ACR21 ABSTL04 @RheumNow https://t.co/92Sn3mCwAi
David Liew drdavidliew ( View Tweet)
#ACR21 L04 @rheumcat on #COVID19 in vaxed pts
▶️87 pts in @rheum_covid w/ ifn s/p full vax. 110 partial vax pts
⭐️25% (22/87) full vax pts hospitalized. 45% on BCDT. 8/22 hospitalized had lung disease, 5 no other co-morbidities. 5 deaths (23%).
@RheumNow https://t.co/DB8C6jKvuU https://t.co/dxUwjTRxxb
Links:
Eric Dein ericdeinmd ( View Tweet)
#ACR21 #Abstr1541 Any tools to help differentiate MAS vs #COVID inflammatory response? Preliminary criteria showed Sensitivity: 79.6%; Specificity: 81.3% within 6 days admission. No Triglyceride/Fibrinogen compared to 2016 ACR-EULAR & 2004 HLH @RheumNow https://t.co/c7pHaVCr5S https://t.co/6irF64qizI
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#ACR21 Abs#1536
#Vaccine uptake in people with #RheumaticDisease
👉🏼High uptake of vaccines in ~240 pts @BrighamWomens
👉🏼84% pts wanted the #COVID19 vaccine
👉🏼Physician recommendation was key determinant of uptake
@RheumNow
https://t.co/us0i5CW5Mi https://t.co/aLZmOPWFR3
Mrinalini Dey DrMiniDey ( View Tweet)
🆕 Updated 2021 ACR Guidance for Adjusting Immunomodulatory Therapy with the COVID-19 Vaccine in Patients with Rheumatic & MSK Diseases
Discussed at #ACR21 COVID-19 Hub!
V4 Link: https://t.co/1SOR9yTQyF https://t.co/PKFKXpLofN
Links:
Mithu Maheswaranathan, MD MithuRheum ( View Tweet)
#ACR21 Year In Review: Factors associated with #COVID deaths in pts with #RMD:
⛔️age, male, HTN/CVD, lung disease, steroid>10mg/d, ⬆️disease activity
⛔️RTX (OR: 4), SFZ (3.6), other IS (2.2), No DMARDs (2.1) vs MTX monotherapy as reference @RheumNow https://t.co/Zd6qXCtGLk https://t.co/YHBEelLqKB
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Meta-analysis from @rheum_covid with @HsiehEvelyn shows that people with rheumatic disease are at⬆️risk of SARS-CoV-2 infection and⬆️mortality from COVID-19. Abstr#0086 #ACR21 @RheumNow #ACRBest https://t.co/B7tWs02gfc
Richard Conway RichardPAConway ( View Tweet)
Dr Patel @jeffsparks @zach_wallace_md comparative cohort study on CD-20 inhibitors and COVID. ⬆️ mortality, aHR 2.16 . Abstr#0085 #ACR21 @RheumNow https://t.co/wyfEBWurRi
Richard Conway RichardPAConway ( View Tweet)
Important differences between vascular pathologies seen in #COVID19 and DIC by Dr. D McGonagle
👉Fibrinogen - normal/sl. ⬆ in PIC-assoc'd COVID19 vs. ⬇ in DIC sec to MAS
@RheumNow #ACR21 #MedTwitter
📌https://t.co/DdmAhVIR51 https://t.co/Xw8LKaKcFd
Links:
sheila RHEUMarampa ( View Tweet)
CARRA survey in SAID pts reported no change in flare frequency w/ COVID19 but many had reduced intensity of fevers during flares. Majority of pts reported mild to moderate symptoms w/ 1/3 had lingering COVID19 symptoms. Abs 1083 #RheumNow #ACR21 @RheumNow https://t.co/qbfsqvXutt https://t.co/6u33VDIexY
Dr. Rachel Tate uptoTate ( View Tweet)
"CH COVID-19: Office Hours: COVID-19 Vaccine in Immune-mediated Inflammatory Disease (IMID) Patients" #ACR21
A great thing about @ACRheum's Convergence is being able to listen to conversations about important topics like booster type & timing specifically for #rhum patients https://t.co/horwWeAen7
International Foundation AiArthritis IFAiArthritis ( View Tweet)
#ACR21
#SLE #COVID19
Use of Telemedicine for follow-up of SLE in COVID19
Wait times lower for telemedicine
Patient satisfaction higher in telemedicine group
More hospitalization, higher switch to in person follow up in telemedicine https://t.co/Y21Vki1uDP
Dr. Laura Lewandowski LauraLewMad11 ( View Tweet)
Join us now at the #ACR21 #COVID19 community hub to hear Kevin Winthrop and @RADoctor discussing about vaccines in patients with RMDs
#ACRAmbassador https://t.co/LivAoLu810
Alessia Alunno alessia_alunno ( View Tweet)
